Detection and Therapeutic Approaches to Age-Related Infertility

  • Fady I. Sharara
  • Richard T. ScottJr.
  • David B. Seifer

Abstract

Two social factors, delayed childbearing and an increase in the prevalence of divorce followed by remarriage, are contributing to a growing number of women in their mid to late thirties who desire fertility at a time when fecundity is declining. One of the most difficult challenges is the evaluation and treatment of these women, who desire fertility but have diminished ovarian reserve. The latter is due to the fact that they frequently do not produce enough quality oocytes to take full advantage of the various options offered by assisted reproductive technologies. In addition, pregnancy rates during natural and assisted cycles are dramatically reduced, and the rate of spontaneous miscarriages is markedly increased.

Keywords

Placebo Drilling Flare Expense Progesterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smith KE, Buyalos RR The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. Fertil Steril 1996;65:35–40.PubMedGoogle Scholar
  2. 2.
    Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril 1995;63:1–11.PubMedGoogle Scholar
  3. 3.
    Cameron IT, O’Shea FC, Rolland JM, et al. Occult ovarian failure: a syndrome of infertility, regular menses, and elevated follicle-stimulating hormone concentrations. J Clin Endocrinol Metab 1988;67: 1190–1194.PubMedCrossRefGoogle Scholar
  4. 4.
    Pearlstone AC, Fournet N, Gambone JC, Pang SC, Buyalos RP. Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age. Fertil Steril 1992;58:674–679.PubMedGoogle Scholar
  5. 5.
    Scott RT, Toner JF, Muasher SJ, et-al. Follicle stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989; 51:651–654.PubMedGoogle Scholar
  6. 6.
    Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784–791.PubMedGoogle Scholar
  7. 7.
    Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas 1988; 10:35–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Reyes FI, Winter JSD, Faiman C. Pituitary-ovarian relationships preceding the menopause. I. A crosssectional study of serum follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 1977; 129: 557–564.PubMedGoogle Scholar
  9. 9.
    Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976;42: 629–636.PubMedCrossRefGoogle Scholar
  10. 10.
    Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975;55:699–706.PubMedCrossRefGoogle Scholar
  11. 11.
    Batista MC, Cartledge TP, Zellmer AW, et al. Effects of aging on menstrual cycle hormones and endometrial maturation. Fertil Steril 1995;64:492–499.PubMedGoogle Scholar
  12. 12.
    Klein NA, Battaglia DE, Fujimoto VY, et al. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81:1038–1045.PubMedCrossRefGoogle Scholar
  13. 13.
    Klein NA, Illingworth PJ, Groome NP, et al. Decreased inhibin-B secretion is associated with the menotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin-A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81:2742–2745.PubMedCrossRefGoogle Scholar
  14. 14.
    Seifer DB, Gardiner AC, Ferreira KA, Peluso JJ. Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Fertil Steril 1996; 66:593–598.PubMedGoogle Scholar
  15. 15.
    Muasher SJ, Oehninger S, Simonetti S, et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50: 298–307.PubMedGoogle Scholar
  16. 16.
    Hughes EG, Robertson DM, Handlesman DJ, et al. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome. J Clin Endocrinol Metab 1990;70:358–364.PubMedCrossRefGoogle Scholar
  17. 17.
    McClachlan RI, Healy DL, Robertson DM, de Kretser DM, Burger HG. Plasma inhibin levels during gonadotropin induced ovarian hyperstimulation for IVF: a new index of follicular function? Lancet 1986;1:1233–1234.CrossRefGoogle Scholar
  18. 18.
    Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. J Clin Endocrinol Metab 1996;81:736–739.PubMedCrossRefGoogle Scholar
  19. 19.
    Seifer DB, Lambert-Messerlian G, Hogan JW, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67: 110–114.PubMedCrossRefGoogle Scholar
  20. 20.
    Scott RT, Hofmann GE, Oehninger S, Muasher SJ. Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril 1990;53:297–302.Google Scholar
  21. 21.
    Martin JSB, Nisker JA, Tummon IS, et al. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril 1996;65:1238–1240.PubMedGoogle Scholar
  22. 22.
    Hansen LM, Batzer FR, Gutmann JN, et al. Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2–5. Hum Reprod 1996;3:486–489.Google Scholar
  23. 23.
    Khalifa E, Toner JP, Muasher SJ, Acosta AA. Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization. Fertil Steril 1992;57:835–839.PubMedGoogle Scholar
  24. 24.
    Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995;64:991–994.PubMedGoogle Scholar
  25. 25.
    Smotrich DB, Widra EA, Gindoff PR, et al. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995;64:1136–1140.PubMedGoogle Scholar
  26. 26.
    Mukherjee T, Copperman AB, Lapinski R, et al. An elevated day three follicle-stimulating hormone: luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertil Steril 1996;65:588–593.PubMedGoogle Scholar
  27. 27.
    Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987;2: 645–647.PubMedCrossRefGoogle Scholar
  28. 28.
    Loumaye E. Billion JM, Mine JM, et al. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertil Steril 1990;53:295–301.PubMedGoogle Scholar
  29. 29.
    Tanbo T, Dale PO, Ludne O, Norman N, Abyholm T. Prediction of response to controlled ovarian hyperstimulation: a comparison of basal and clomiphene citrate-stimulated follicle stimulating hormone levels. Fertil Steril 1990;53:295–301.Google Scholar
  30. 30.
    Scott RT, Leonardi MR, Hofmann GE, et al. A prospective evaluation of clomiphene citrate challenge test screening in the general infertility population. Obstet Gynecol 1993;82:539–545.PubMedCrossRefGoogle Scholar
  31. 31.
    Scott RT, Opsahl MS, Leonardi MR, et al. Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Hum Reprod 1995;10:1706–1710.PubMedGoogle Scholar
  32. 32.
    Adeno M, Gallagher H. Cigarette smoking and the age of menopause. Ann Hum Biol 1982;9:121–130.CrossRefGoogle Scholar
  33. 33.
    Jick H, Porter J, Morrison AS. Relationship between smoking and age of natural menopause. Lancet 1997;1:1354–1354.Google Scholar
  34. 34.
    Sharara FI, Beatse SN, Leonardi MR, Navot D, Scott RT. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test (CCCT). Fertil Steril 1994;62:257–262.PubMedGoogle Scholar
  35. 35.
    Hughes EG, Yeo J, Claman P, et al. Cigarette smoking and the outcomes of in vitro fertilization: measurement of effect size and levels of action. Fertil Steril 1994;62:807–814.PubMedGoogle Scholar
  36. 36.
    Sterazik K, Strehler E, De Santo M, et al. Influence of smoking on fertility in women attending an in vitro fertilization program. Fertil Steril 1996;65:810–814.Google Scholar
  37. 37.
    Hershlag A, Lesser M, Montefusco D, et al. Interinstitutional variability of follicle-stimulating hormone and estradiol levels. Fertil Steril 1992;58:1123–1126.PubMedGoogle Scholar
  38. 38.
    Scifer DB, Canick JA, Seltman HJ, Frishman GN, Berk CA. Abstract P368. In: 39th Annual Meeting of the Society for Gynecologic Investigation, San Antonio, TX, 1993.Google Scholar
  39. 39.
    Syrop CH, Dawson JD, Husman KJ, Sparks AE, Van Voorhis BJ. Ovarian volume may predict assisted reproductive outcomes better than follicle hormone concentration on day 3. Hum Reprod 1999; 14:1752.PubMedCrossRefGoogle Scholar
  40. 40.
    Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65:961–965.PubMedGoogle Scholar
  41. 41.
    Droesch K, Muasher ST, Brzyski R, et al. Value of suppression with a GnRH-a prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril 1989;51:292–295.PubMedGoogle Scholar
  42. 42.
    Muasher SJ. Treatment of low responders. J Assist Reprod Genet 1993;10:112–114.PubMedCrossRefGoogle Scholar
  43. 43.
    Feldberg D, Farhi J, Ashkenazi J, et al. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high folliclestimulation hormone levels. Fertil Steril 1994;62: 343–346.PubMedGoogle Scholar
  44. 44.
    Garcia JE, Padilla SL, Bayati J, Baramki TA. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril 1990;53:302–305.PubMedGoogle Scholar
  45. 45.
    Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil Steril 1990; 53:288–294.PubMedGoogle Scholar
  46. 46.
    Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril 1996;65:796–799.PubMedGoogle Scholar
  47. 47.
    Navot D, Rosenwaks Z, Anderson F, Hodgen GD. Gonadotropin releasing hormone agonist-induced ovarian hyperstimulation: low dose side effects in women and monkeys. Fertil Steril 1991 ;55:1069–1075.PubMedGoogle Scholar
  48. 48.
    Scott RT, Navot D. Enhancement of ovarian responsiveness with micro-doses of GnRH-agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880–885.PubMedGoogle Scholar
  49. 49.
    Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 1997;67:93–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Adashi EY, Resnick CE, Hernandez ER, et al. Insulin like growth factor I as an intra-ovarian regulator: basic and clinical implications. Ann NY Acad Sci 1991;626:161–167.PubMedCrossRefGoogle Scholar
  51. 51.
    Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992;13:641–669.PubMedGoogle Scholar
  52. 52.
    Sharara FI, Nieman LK. Identification and cellular localization of growth hormone receptor gene expression in the human ovary. J Clin Endocrinol Metab 1994;79:670–672.PubMedCrossRefGoogle Scholar
  53. 53.
    El-Roiey A, Chen X, Roberts VJ, et al. Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab 1993;77:1411–1418.CrossRefGoogle Scholar
  54. 54.
    Menashe Y, Lunenfeld B, Pariente C, Frenkel Y, Mashiach S. Can GH increase after Clonidine administration predict the dose of human menopausal hormone needed for induction of ovulation. Fertil Steril 1990;53:432–435.PubMedGoogle Scholar
  55. 55.
    Shoham Z, European and Australian Multicenter study. Cotreatment with growth hormone and gonadotropin for ovulation induction in hypogonadotropic patients: a prospective, randomized, placebo-controlled, dose-response study. Fertil Steril 1995;64: 917–923.Google Scholar
  56. 56.
    Bergh C, Hillensjo T, Wikland M, et al. Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertil Steril 1994;62:113–120.PubMedGoogle Scholar
  57. 57.
    Owen EJ, West C, Mason BA, Jacobs HS. Co-treatment with growth hormone of suboptimal responders in IVF-ET. Hum Reprod 1991;6:529–533.Google Scholar
  58. 58.
    Younis JS, Simon A, Koren R, et al. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized, placebo controlled double blind study. Fertil Steril 1992; 58:575–580.PubMedGoogle Scholar
  59. 59.
    59. Suikkara AM, MacLachlan V, Koistinen R, Seppala M, Healy DL. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 1996; 65:800–805.Google Scholar
  60. 60.
    Wildra EA, Gindoff PR, Smotrich DB, Stillman RJ. Achieving multiple-order embryo transfer identifies women over 40 years of age with impaired in vitro fertilization outcome. Fertil Steril 1996;65:103–108.Google Scholar
  61. 61.
    Meldrum DR. Female reproduction aging-ovarian and uterine factors. Fertil Steril 1993;59:1–5.PubMedGoogle Scholar
  62. 62.
    Cohen J, Alikani M, Trowbridge J, Rosenwaks Z. Implantation enhancement by selective assisted hatching using zona drilling of embryos with poor prognosis. Hum Reprod 1992;7:685–691.PubMedGoogle Scholar
  63. 63.
    Schoolcraft WB, Schlenker T, Gee M, Jones GS, Jones HW. Efficacy of assisted hatching in poor prognosis IVF candidates. Fertil Steril 1994;62:551–554.PubMedGoogle Scholar
  64. 64.
    Hu Y, Hoffman DI, Maxson WS, Ory SJ. Clinical application of non-selective assisted hatching of human embryos. Fertil Steril 1996;66:991–994.PubMedGoogle Scholar
  65. 65.
    Flood JT, Chillik CF, van Uem JFHM, Iritani A, Hodgen GD. Ooplasmic transfusion: prophase germinal vesicle oocytes made developmentally competent by microinjection of metaphase II egg cytoplasm. Fertil Steril 1990;53:1049–1054.PubMedGoogle Scholar
  66. 66.
    Keefe DL, Niven-Fairchild T, Powell S, Buradagunta S. Mitochondrial deoxyribonucleic acid deletion in oocytes and reproductive aging in women. Fertil Steril 1995;64:577–583.PubMedGoogle Scholar
  67. 67.
    Battaglia DE, Goodwin P, Klein NA, Soules MR. Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women. Hum Reprod 1996;11:2217–2222.PubMedGoogle Scholar

Suggested Reading

  1. Chang M, Chiang C, Hsich T, et al. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69:505.PubMedCrossRefGoogle Scholar
  2. Hoffman G, Danforth D, Scifer D. Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 1998;69:474.CrossRefGoogle Scholar
  3. Reuss M, Kline J, Santos R, et al. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol 1996;174:624.CrossRefGoogle Scholar
  4. Santoro N, Tovaghogol A, Skurnick J. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 1999;71:658.PubMedCrossRefGoogle Scholar
  5. Scifer D, Scott R, Bergh P, et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin-B prior to a rise in day 3 FSH. Fertil Steril 1999;72:63.PubMedCrossRefGoogle Scholar
  6. Sharara F, McClamrock H. The effect of aging on ovarian volume measurements in infertile women. Obstet Gynecol 1999;94:57.PubMedCrossRefGoogle Scholar
  7. Sharara F, Scifer DB. New Methods for Assessing Ovarian Reserve. OBG Management Volume 12, issue 10, pages 61–69, 2000.Google Scholar
  8. Welt C, McNicholl D, Taylor A, Hall J. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999;84:105.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2002

Authors and Affiliations

  • Fady I. Sharara
  • Richard T. ScottJr.
  • David B. Seifer

There are no affiliations available

Personalised recommendations